Liraglutide (Victoza) is a daily GLP-1 agonist, semaglutide (Ozempic) is a weekly GLP-1 agonist
The optimal cycling pattern has not been determined through research, and individual responses may vary
*Important: If you cannot tolerate dose escalation (an increase after the 4-week period), you may request delaying dose escalation for 4-weeks
As a synthetic growth hormone-releasing peptide, IGF-1 LR3 is renowned for its ability to promote anabolic muscle cell signaling and extend the half-life of growth factor analogs
Ensure the needle is fully engaged and wait for the click or the visual indicator to confirm the dose is complete
Obesity is also a cancer risk Its important to remember that obesity itself is a well established risk factor for several cancers, including breast, colon, liver and uterine cancers